Ondansetron, prochlorperazine, and dexamethasone have similar effects on prevention of delayed chemotherapy-induced nausea and vomiting

Cancer Treatment Reviews

Volumn 32, Issue 1, 2006, Pages 50-54

  Navari, Rudolph M ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APREPITANT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; METOCLOPRAMIDE; NEUROKININ 1 RECEPTOR ANTAGONIST; OLANZAPINE; ONDANSETRON; PACLITAXEL; PALONOSETRON; PROCHLORPERAZINE; SEROTONIN ANTAGONIST;

ANXIETY DISORDER; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONCENTRATION LOSS; CONSCIOUSNESS DISORDER; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HEARTBURN; HUMAN; LUNG CANCER; LYMPHOMA; NAUSEA AND VOMITING; PATIENT SATISFACTION; RESTLESSNESS; SHORT SURVEY; URINARY TRACT CANCER; VISUAL ANALOG SCALE; WEAKNESS;

EID: 31544438832     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2005.12.003     Document Type: Note

References (14)

1. P.J. Hesketh New treatment options for chemotherapy-induced nausea and vomiting Support Care Cancer 12 2004 550-554
2. R.M. Navari Pathogenesis-based treatment of chemotherapy induced nausea and vomiting. Two new agents J Support Oncol 1 2003 89-103
3. The Italian Group for Antiemetic Research Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide J Clin Oncol 22 2004 725-729
4. F. Roila D. Warr R. et al. Clark-Snow Delayed emesis: Moderately emetogenic chemotherapy Support Care Cancer 13 2005 104-108
5. The Italian Group for Antiemetic Research Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy N Engl J Med 342 2000 1554-1559
6. O. Geling H.G. Eichler Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications J Clin Oncol 23 2005 1289-1294
7. J.T. Hickok J.A. Roscoe G.R. Morrow et al. 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: A URCC CCOP randomized controlled trial Lancet Oncol 6 2005 765-772
8. J.T. Hickok J.A. Roscoe G.R. Morrow D.K. King J.N. Atkins J.R. Fitch Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5- Hydroxytryptamine-3 antiemetics Cancer 97 2003 2880-2886
9. R.M. Navari Aprepitant: A neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting Expert Rev Anticancer Ther 4 2004 715-724
10. T.M. Dando C.M. Perry Aprepitant: A review of its use in the prevention of chemotherapy-induced nausea and vomiting Drugs 64 2004 777-794
11. S. Passik R.M. Navari S. Jung et al. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: A Hoosier Oncology Group study Cancer Invest 22 2004 383-388
12. R.M. Navari L.H. Einhorn et al. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier Oncology Group study Support Care Cancer 13 2005 529-534
13. National Comprehensive Cancer Network. Available from: http://www.nccn.org.
14. Multinational Association of Supportive Care in Cancer. Available from: http://www.mascc.org.